Testa vår nya webbplats och uppdaterade nyhetsrum för att ta del av aktuella nyheter, rapporter och mycket mer.

Eevia Health Plc received new sales order for Feno-Sambucus™ for the equivalent of c. SEK 34.4 million

Following a successful exhibition at the Supply Side West trade show in Las Vegas, US, last week, Eevia Health ("Eevia" or "The Company") received an order for the Feno-Sambucus™ equaling a revenue of SEK 34.4 million. The order is a new contractual volume section related to a five-year Sales Agreement with a US brand owner. The new section has adjusted prices and terms.

Eevia Health Plc is a leading health ingredient manufacturer from Finland and is currently the largest manufacturer of elderberry extract in the world. Eevia has received a call-off for quantities for November 2022 - December 2023 for Feno-Sambucus, an Elderberry extract. The value of the call-off equals a revenue of SEK 34.4 million. The order is linked to a multi-year Sales Agreement with an essential international customer. The customer uses the elderberry ingredients from Eevia in nutraceutical formulations for sales primarily in the US market.

Eevia initially entered the Sales Agreement on June 11th, 2021. The new volume sections of the Sales Agreement, which the parties refer to as Programs, are contracted at adjusted prices. The reason is that the new program will consume raw materials purchased at different prices than the earlier programs. All raw materials for this order have already been purchased and are in stock in Finland.

The end customer is an internationally recognized brand leader in the marketplace with a global footprint. The group had sales of USD 1,4 billion in 2021. It offers over 500 premium dietary supplements, including single herbs, vitamins, minerals, and specialty formulas sold under the Company's well-recognized brands in over 60 countries.

CEO Stein Ulve comments: "This call-off secures an important part of our order book and sales revenues going into 2023. We have improved our yields and productivity and adjusted the margins so that we can expect acceptable profitability for this volume."

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          

Email: [email protected]                      

Telephone: +358 400 22 5967                         

This information is such that Eevia Health Plc is required to make it public in accordance with the EU's Market Abuse Regulation (MAR). The information was made public by the Company's contact person above on November 8th, 2022, at 17:30 CET.

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.

To learn more, please visit  www.eeviahealth.com or follow Eevia Health on [email protected] 

Eevia Health Plc receives a USD 200K sales order for Feno-Sambucus™ 7 Organic

Eevia Health ("Eevia" or "The Company") received a sales order from a US customer for the elderberry extract Feno-Sambucus™ 7 Organic for a value of just over USD 200k or EUR 187k.


FLAGGING OF A TRANSACTION BETWEEN PMDRS IN EEVIA HEALTH PLC

Stein Ulve, the Chief Executive Officer (CEO) of Eevia Health Plc, ("Eevia" or "The Company") has sold 112 782 shares in The Company to Harri Salo, the Chief Manufacturing Officer (CMO) of Eevia.


CORRECTION Eevia Health Plc receives a 150 KSEK / 13 KEUR sales order for a Bilberry extract product

Due to a misjudgement, the MAR label was added to the original press release. The press release did not contain any insider information or other reason for the MAR label. This press release is a correction without the MAR label. 

Eevia Health Plc ("Eevia" or "The Company") has received a 13 KEUR sales order for Bilberry extract from its customer in South-Korea.


Eevia Health Plc receives a 150 KSEK / 13 KEUR sales order for a Bilberry extract product

Eevia Health Plc ("Eevia" or "The Company") has received a 13 KEUR sales order for Bilberry extract from its customer in South-Korea.


Last day of trading in paid subscription shares (Swedish: BTA) in Eevia Health Plc

Eevia Health Plc's ("Eevia" or "the Company") preferential rights issue has now been registered with the Finnish Trade Register. Paid Subscription Shares (Swedish: BTA) will thus be replaced by ordinary shares. The last day for trading with BTA on Spotlight Stock Market is 22 December 2022, and new shares are expected to be booked into the respective custodian/VP account on 29 December 2022.


EEVIA HEALTH PLC: FLAGGING NOTIFICATION OF CHANGE OF HOLDINGS BY CEO

Stein Ulve, the CEO of Eevia Health Plc, ("Eevia" or "The Company"), subscribed for 489 996 shares in the preferential rights issue, which Eevia concluded on November 17th. The equity issue was for 14 376 015 shares and was fully subscribed. Stein Ulve had 1 907 500 subscription rights, but he subscribed for 489 996 shares. Consequently, he was diluted under the flagging threshold of 10%.


EEVIA HEALTH PLC: FLAGGING NOTIFICATION OF NEW SHAREHOLDING

Eevia Health Plc ("the Company" or "Eevia") has become aware that Marizoe Actives S.L. from Madrid, Spain has subscribed for 1 517 459 shares in the preferential rights issue, which Eevia concluded on November 17th. The equity issue was for 14 376 015 shares and was fully subscribed, leading to a new total of shares of 30 349 371. Marizoe Actives S.L. had no shares before the issue and with the subscription, Marizoe has 5.01% of the new outstanding shares.


Eevia Health Plc received small initial sales order for Feno-Sambucus™ from Australia

Eevia Health ("Eevia" or "The Company") received a start order for the Feno-Sambucus™ worth SEK 110 000 from its Australian distributor Ingredient Plus. The order is a new start order for an Australian brand owner.


Eevia Health Plc receives a 445 KSEK / 41 KEUR sales order for a Bilberry extract product

Eevia Health Plc's ("Eevia" or "The Company") has received a 41 KEUR sales order for Bilberry extract from its distributor in France Natural Ingredients.


Eevia Health Plc commissions new analytical equipment for analyzing anthocyanins and polyphenols

Eevia Health has commissioned a new High-Performance Liquid Chromatography (HPLC) analytical equipment from Shimadzu, which significantly increases the capacity to undertake analyses of polyphenols.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted